Nintedanib

證據等級: L5

預測適應症: 3 個

Nintedanib: From Idiopathic Pulmonary Fibrosis to Dermatofibrosarcoma Protuberans

One-Sentence Summary

Nintedanib is a triple angiokinase inhibitor (targeting VEGFR/FGFR/PDGFR) internationally approved for idiopathic pulmonary fibrosis (IPF) and, in combination with docetaxel, for non-small cell lung cancer. The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), but currently 0 clinical trials and only 1 non-drug-specific review article support this direction — the case rests on mechanistic plausibility rather than direct clinical evidence.

Note: this evidence pack contains no Norway licensing data for nintedanib (market status: unmarketed, 0 authorizations), so the original indication above reflects the drug's known international approvals rather than a Norway-specific label.

Quick Overview

Item	Content
Original Indication	Idiopathic pulmonary fibrosis (IPF); NSCLC (in combination with docetaxel) — general international indication; no Norway-specific license text available
Predicted New Indication	Dermatofibrosarcoma protuberans
TxGNN Prediction Score	99.15%
Evidence Level	L4
Norway Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Nintedanib is described in the evidence pack's repurposing rationale as a triple angiokinase inhibitor, with activity against PDGFRα/β in addition to VEGFR and FGFR (the drug-level original_moa field itself is flagged as a data gap — DG002 — but this mechanistic detail is preserved in the rationale text). This PDGFR-inhibitory activity is the pharmacological basis for the DFSP prediction.

DFSP is a well-characterized soft tissue tumor driven by the COL1A1-PDGFB fusion gene, which causes constitutive activation of the PDGFRB receptor — this is an established, textbook oncogenic mechanism, and it is precisely why the current standard-of-care agent for DFSP (imatinib) works by inhibiting PDGFR. Because nintedanib also inhibits PDGFR signaling, there is a plausible theoretical overlap between its pharmacology and DFSP's driver pathway, which is consistent with the model's very high prediction score (0.9915).

However, this remains a mechanism-level hypothesis, not a demonstrated clinical effect. No nintedanib-specific clinical trial or case data for DFSP currently exists; the only supporting literature is a general review of PDGFR-inhibitor drug class pharmacology, not a nintedanib/DFSP-specific study.

Two additional candidates were flagged by the model with similar scores — liposarcoma (0.9913, rank 8457) and ovarian myxoid liposarcoma (0.9911, rank 8580) — but both are evidence level L5 (model prediction only, no supporting trials or literature) and carry weaker or unconfirmed mechanistic rationale (liposarcoma subtypes show only inconsistent PDGFR/FGFR upregulation; myxoid liposarcoma is driven by FUS-DDIT3/EWSR1-DDIT3, a pathway with no established link to nintedanib's targets). Both are recommended Hold and are not pursued further in this report.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29408302	2018	Review	Pharmacological Research	Reviews the role of small-molecule PDGFR inhibitors (as a drug class) in treating neoplastic disorders; discusses PDGF/PDGFR biology relevant to tumors like DFSP, but does not report nintedanib-specific or DFSP-specific clinical data

Norway Market Information

Nintedanib is currently not marketed in Norway (0 marketing authorizations on record), so no license/product table is available.

Safety Considerations

Please refer to the package insert for safety information.

(No structured key warnings, contraindications, or drug-interaction data are currently available in this evidence pack — TFDA/Norway package insert data is flagged as a Blocking data gap, DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale:

The mechanistic rationale (PDGFR inhibition overlapping with DFSP's COL1A1-PDGFB driver pathway) is biologically plausible and mirrors the established mechanism of the current DFSP standard of care (imatinib), which is why TxGNN assigns a very high score. However, there are zero clinical trials and no drug-specific literature confirming this in practice — evidence level L4 means this is currently a research hypothesis, not a validated repurposing candidate.

To proceed, the following is needed:

Norway/TFDA package insert data — key warnings and contraindications (DG001, Blocking)
Confirmed structured mechanism-of-action documentation from DrugBank (DG002, High)
Preclinical (in vitro/in vivo) or case-report evidence of nintedanib activity specifically in DFSP
Clarification of Norway regulatory/market pathway, given the drug currently has no local marketing authorization
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.